Tocagen Phase III study in brain cancer fails, sending shares plummeting
The company said Thursday morning that its study failed to meet its primary endpoint in high-grade gliomas. Shares of the company fell more than 80 percent on the Nasdaq.
The company said Thursday morning that its study failed to meet its primary endpoint in high-grade gliomas. Shares of the company fell more than 80 percent on the Nasdaq.